Business Context and Reporting Period
This Form 8-K Current Report was filed by Seres Therapeutics, Inc. on August 14, 2020, regarding events occurring on August 12, 2020. The filing details the entry into material definitive agreements for a public offering of common stock and a concurrent private placement.
Key Financial Metrics and Transaction Details
- Public Offering: Sale of 10,500,000 shares of common stock at a public offering price of $21.50 per share.
- Over-Allotment Option: Underwriters exercised their option in full to purchase an additional 1,575,000 shares at the same price.
- Concurrent Placement: Sale of 959,002 shares to Société des Produits Nestlé S.A. at a purchase price of $20.855 per share.
- Expected Net Proceeds: Approximately $232.2 million, or approximately $264.0 million if the over-allotment option is fully exercised (which it was).
- Liquidity Outlook: Management believes existing cash, cash equivalents, investments, and net proceeds will fund operations into the first half of 2022.
Material Changes and Agreements
The Company entered into two primary agreements on August 12, 2020:
- Underwriting Agreement: Executed with Cowen and Company, LLC and Piper Sandler & Co. as representatives. The closing was expected on or about August 17, 2020.
- Securities Purchase Agreement: Executed with Nestlé for the concurrent placement. Closing is contingent upon the public offering closing and satisfaction of customary conditions, including potential Hart-Scott-Rodino (HSR) Antitrust clearance.
Guidance, Use of Proceeds, and Risks
Use of Proceeds: The Company intends to use net proceeds to advance clinical development of product candidates, support commercialization and manufacturing activities, and for general corporate and working capital purposes.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Key risks include market conditions, satisfaction of closing conditions, and the requirement for HSR clearance for the full amount of the Nestlé placement. The filing references risk factors detailed in the Company's Form 10-Q filed on July 28, 2020.
Investor Verification Checklist
- Verify the final closing date of the offering and concurrent placement (expected on or about August 17, 2020).
- Confirm the final net proceeds received after deducting underwriting discounts and offering expenses.
- Monitor the status of Hart-Scott-Rodino (HSR) clearance regarding the Nestlé concurrent placement.
- Review the full text of the Underwriting Agreement (Exhibit 1.1) and Securities Purchase Agreement (Exhibit 10.1) for specific covenants and termination provisions.